Jim Hitchin, SpectraScience’s CEO, said: “This patent is important to the company’s optical biopsy technology because it provides protection in the areas of tissue surveillance, characterization, diagnosis and treatment. It supports the company’s fundamental technology of non-invasive, low-level laser diagnosis of pre-cancerous and cancerous tissue.
“This is another key patent in our intellectual property portfolio that underscores our commitment at SpectraScience to develop better, more reliable cancer screening technologies.”